speb/financial-data huggingface dataset:
RX.V balance_sheet (annual, 2025-12-31) — Accounts Payable: 6147907.00
RX.V balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 6147907.00
RX.V balance_sheet (annual, 2025-12-31) — Accounts Receivable: 3733176.00
RX.V balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 3733176.00
RX.V balance_sheet (annual, 2025-12-31) — Accrued Interest Receivable: 659944.00
RX.V balance_sheet (quarterly, 2025-12-31) — Accrued Interest Receivable: 659944.00
RX.V balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -2437193.00
RX.V balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -2437193.00
RX.V balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 2163428.00
RX.V balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 2163428.00
RX.V income_statement (annual, 2025-12-31) — Amortization: 580192.00
RX.V income_statement (quarterly, 2025-12-31) — Amortization: 155498.00
RX.V cash_flow (annual, 2025-12-31) — Amortization Cash Flow: 580192.00
RX.V cash_flow (quarterly, 2025-12-31) — Amortization Cash Flow: 155498.00
RX.V cash_flow (annual, 2025-12-31) — Amortization Of Intangibles: 580192.00
RX.V cash_flow (quarterly, 2025-12-31) — Amortization Of Intangibles: 155498.00
RX.V income_statement (annual, 2025-12-31) — Amortization Of Intangibles Income Statement: 580192.00
RX.V income_statement (quarterly, 2025-12-31) — Amortization Of Intangibles Income Statement: 155498.00
RX.V cash_flow (annual, 2025-12-31) — Asset Impairment Charge: 0.00
RX.V income_statement (annual, 2025-12-31) — Basic Average Shares: 11263255.00
RX.V income_statement (quarterly, 2025-12-31) — Basic Average Shares: 11263255.00
RX.V income_statement (annual, 2025-12-31) — Basic EPS: 0.80
RX.V income_statement (quarterly, 2025-12-31) — Basic EPS: 0.18
RX.V cash_flow (annual, 2025-12-31) — Beginning Cash Position: 12113376.00
RX.V cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 16568691.00
RX.V balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 1330455.00
RX.V balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 1330455.00
RX.V cash_flow (annual, 2025-12-31) — Capital Expenditure: -389808.00
RX.V cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -17363.00
RX.V balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 841104.00
RX.V balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 841104.00
RX.V balance_sheet (annual, 2025-12-31) — Capital Stock: 5245760.00
RX.V balance_sheet (quarterly, 2025-12-31) — Capital Stock: 5245760.00
RX.V balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 21794686.00
RX.V balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 21794686.00
RX.V balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 28651823.00
RX.V balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 28651823.00
RX.V cash_flow (annual, 2025-12-31) — Cash Dividends Paid: -2252222.00
RX.V cash_flow (quarterly, 2025-12-31) — Cash Dividends Paid: -563114.00
RX.V balance_sheet (annual, 2025-12-31) — Cash Equivalents: 1509138.00
RX.V balance_sheet (quarterly, 2025-12-31) — Cash Equivalents: 1509138.00
RX.V balance_sheet (annual, 2025-12-31) — Cash Financial: 20285548.00
RX.V balance_sheet (quarterly, 2025-12-31) — Cash Financial: 20285548.00
RX.V cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: -3407391.00
RX.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: -638778.00
RX.V cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: 4092668.00
RX.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: 2389794.00
RX.V cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: 9009146.00
RX.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 3487434.00
RX.V cash_flow (annual, 2025-12-31) — Change In Account Payable: 2148969.00
RX.V cash_flow (annual, 2025-12-31) — Change In Income Tax Payable: 9115.00
RX.V cash_flow (annual, 2025-12-31) — Change In Inventory: -1240094.00
RX.V cash_flow (quarterly, 2025-12-31) — Change In Inventory: -668816.00
RX.V cash_flow (annual, 2025-12-31) — Change In Other Working Capital: -388923.00
RX.V cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: 348652.00
RX.V cash_flow (annual, 2025-12-31) — Change In Payable: 2158084.00
RX.V cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 2158084.00
RX.V cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: -249717.00
RX.V cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: 13994.00
RX.V cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: 151961.00
RX.V cash_flow (annual, 2025-12-31) — Change In Receivables: -1449746.00
RX.V cash_flow (quarterly, 2025-12-31) — Change In Receivables: 1579125.00
RX.V cash_flow (annual, 2025-12-31) — Change In Tax Payable: 9115.00
RX.V cash_flow (annual, 2025-12-31) — Change In Working Capital: -906685.00
RX.V cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 1161205.00
RX.V cash_flow (annual, 2025-12-31) — Changes In Cash: 9694423.00
RX.V cash_flow (quarterly, 2025-12-31) — Changes In Cash: 5238450.00
RX.V balance_sheet (annual, 2025-12-31) — Common Stock: 5245760.00
RX.V balance_sheet (quarterly, 2025-12-31) — Common Stock: 5245760.00
RX.V cash_flow (annual, 2025-12-31) — Common Stock Dividend Paid: -2252222.00
RX.V cash_flow (quarterly, 2025-12-31) — Common Stock Dividend Paid: -563114.00
RX.V balance_sheet (annual, 2025-12-31) — Common Stock Equity: 41465506.00
RX.V balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 41465506.00
RX.V cash_flow (annual, 2025-12-31) — Common Stock Payments: -215000.00
RX.V cash_flow (quarterly, 2025-12-31) — Common Stock Payments: 780953.00
RX.V income_statement (annual, 2025-12-31) — Cost Of Revenue: 10088955.00
RX.V income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 2225569.00
RX.V balance_sheet (annual, 2025-12-31) — Current Assets: 39792961.00
RX.V balance_sheet (quarterly, 2025-12-31) — Current Assets: 39792961.00
RX.V balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 214360.00
RX.V balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 214360.00
RX.V balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 214360.00
RX.V balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 214360.00
RX.V balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 424275.00
RX.V balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 424275.00
RX.V balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 424275.00
RX.V balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 424275.00
RX.V balance_sheet (annual, 2025-12-31) — Current Liabilities: 7215608.00
RX.V balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 7215608.00
RX.V cash_flow (annual, 2025-12-31) — Deferred Income Tax: -88220.00
RX.V cash_flow (quarterly, 2025-12-31) — Deferred Income Tax: -131441.00
RX.V cash_flow (annual, 2025-12-31) — Deferred Tax: -88220.00
RX.V cash_flow (quarterly, 2025-12-31) — Deferred Tax: -131441.00
RX.V cash_flow (annual, 2025-12-31) — Depreciation: 272299.00
RX.V cash_flow (quarterly, 2025-12-31) — Depreciation: 70964.00
RX.V cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 852491.00
RX.V cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 226462.00
RX.V income_statement (annual, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 852491.00
RX.V income_statement (quarterly, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 226462.00
RX.V cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 852491.00
RX.V cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 226462.00
RX.V income_statement (annual, 2025-12-31) — Depreciation And Amortization In Income Statement: 852491.00
RX.V income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 226462.00
RX.V income_statement (annual, 2025-12-31) — Depreciation Income Statement: 272299.00
RX.V income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 70964.00
RX.V income_statement (annual, 2025-12-31) — Diluted Average Shares: 11263255.00
RX.V income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 11263255.00
RX.V income_statement (annual, 2025-12-31) — Diluted EPS: 0.80
RX.V income_statement (quarterly, 2025-12-31) — Diluted EPS: 0.18
RX.V income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: 9012232.00
RX.V income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 1991788.00
RX.V income_statement (annual, 2025-12-31) — EBIT: 12079365.00
RX.V income_statement (quarterly, 2025-12-31) — EBIT: 2489866.00
RX.V income_statement (annual, 2025-12-31) — EBITDA: 12931856.00
RX.V income_statement (quarterly, 2025-12-31) — EBITDA: 2716328.00
RX.V cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: -13113.00
RX.V cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: -12455.00
RX.V cash_flow (annual, 2025-12-31) — End Cash Position: 21794686.00
RX.V cash_flow (quarterly, 2025-12-31) — End Cash Position: 21794686.00
RX.V cash_flow (annual, 2025-12-31) — Financing Cash Flow: -3407391.00
RX.V cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: -638778.00
RX.V balance_sheet (annual, 2025-12-31) — Finished Goods: 4842091.00
RX.V balance_sheet (quarterly, 2025-12-31) — Finished Goods: 4842091.00
RX.V balance_sheet (annual, 2025-12-31) — Foreign Currency Translation Adjustments: -184667.00
RX.V balance_sheet (quarterly, 2025-12-31) — Foreign Currency Translation Adjustments: -184667.00
RX.V cash_flow (annual, 2025-12-31) — Free Cash Flow: 8619338.00
RX.V cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 3470071.00
RX.V cash_flow (annual, 2025-12-31) — Gain Loss On Investment Securities: 29397.00
RX.V cash_flow (quarterly, 2025-12-31) — Gain Loss On Investment Securities: 7147.00
RX.V income_statement (annual, 2025-12-31) — Gain On Sale Of Security: -42889.00
RX.V income_statement (quarterly, 2025-12-31) — Gain On Sale Of Security: -87167.00
RX.V balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -184667.00
RX.V balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -184667.00
RX.V income_statement (annual, 2025-12-31) — General And Administrative Expense: 12339049.00
RX.V income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 3123518.00
RX.V balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 4797073.00
RX.V balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 4797073.00
RX.V balance_sheet (annual, 2025-12-31) — Gross PPE: 3419930.00
RX.V balance_sheet (quarterly, 2025-12-31) — Gross PPE: 3419930.00
RX.V income_statement (annual, 2025-12-31) — Gross Profit: 32963028.00
RX.V income_statement (quarterly, 2025-12-31) — Gross Profit: 7446354.00
RX.V balance_sheet (annual, 2025-12-31) — Hedging Assets Current: 0.00
RX.V balance_sheet (quarterly, 2025-12-31) — Hedging Assets Current: 0.00
RX.V balance_sheet (annual, 2025-12-31) — Held To Maturity Securities: 3293957.00
RX.V balance_sheet (quarterly, 2025-12-31) — Held To Maturity Securities: 3293957.00
RX.V income_statement (annual, 2025-12-31) — Impairment Of Capital Assets: 0.00
RX.V cash_flow (annual, 2025-12-31) — Income Tax Paid Supplemental Data: 3096885.00
RX.V cash_flow (quarterly, 2025-12-31) — Income Tax Paid Supplemental Data: 2049895.00
RX.V balance_sheet (annual, 2025-12-31) — Income Tax Payable: 405458.00
RX.V balance_sheet (quarterly, 2025-12-31) — Income Tax Payable: 405458.00
RX.V income_statement (annual, 2025-12-31) — Insurance And Claims: 214152.00
RX.V income_statement (quarterly, 2025-12-31) — Insurance And Claims: 53410.00
RX.V income_statement (annual, 2025-12-31) — Interest Expense: 49353.00
RX.V income_statement (quarterly, 2025-12-31) — Interest Expense: 11478.00
RX.V income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 49353.00
RX.V income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 11478.00
RX.V income_statement (annual, 2025-12-31) — Interest Income: 809100.00
RX.V income_statement (quarterly, 2025-12-31) — Interest Income: 187767.00
RX.V income_statement (annual, 2025-12-31) — Interest Income Non Operating: 809100.00
RX.V income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 187767.00
RX.V cash_flow (annual, 2025-12-31) — Interest Paid Cff: -49353.00
RX.V cash_flow (quarterly, 2025-12-31) — Interest Paid Cff: -11478.00
RX.V cash_flow (annual, 2025-12-31) — Interest Received Cfi: 610408.00
RX.V cash_flow (quarterly, 2025-12-31) — Interest Received Cfi: 330692.00
RX.V balance_sheet (annual, 2025-12-31) — Inventory: 6416204.00
RX.V balance_sheet (quarterly, 2025-12-31) — Inventory: 6416204.00
RX.V balance_sheet (annual, 2025-12-31) — Invested Capital: 41465506.00
RX.V balance_sheet (quarterly, 2025-12-31) — Invested Capital: 41465506.00
RX.V cash_flow (annual, 2025-12-31) — Investing Cash Flow: 4092668.00
RX.V cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: 2389794.00
RX.V balance_sheet (annual, 2025-12-31) — Investmentin Financial Assets: 3293957.00
RX.V balance_sheet (quarterly, 2025-12-31) — Investmentin Financial Assets: 3293957.00
RX.V balance_sheet (annual, 2025-12-31) — Investments And Advances: 3293957.00
RX.V balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 3293957.00
RX.V balance_sheet (annual, 2025-12-31) — Leases: 680511.00
RX.V balance_sheet (quarterly, 2025-12-31) — Leases: 680511.00
RX.V balance_sheet (annual, 2025-12-31) — Loans Receivable: 80395.00
RX.V balance_sheet (quarterly, 2025-12-31) — Loans Receivable: 80395.00
RX.V balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 626744.00
RX.V balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 626744.00
RX.V balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 626744.00
RX.V balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 626744.00
RX.V cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -196627.00
RX.V cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: -51774.00
RX.V balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 1132947.00
RX.V balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 1132947.00
RX.V cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: -215000.00
RX.V cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 780953.00
RX.V income_statement (annual, 2025-12-31) — Net Income: 9012232.00
RX.V income_statement (quarterly, 2025-12-31) — Net Income: 1991788.00
RX.V income_statement (annual, 2025-12-31) — Net Income Common Stockholders: 9012232.00
RX.V income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 1991788.00
RX.V income_statement (annual, 2025-12-31) — Net Income Continuous Operations: 9012232.00
RX.V income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 1991788.00
RX.V income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 9012232.00
RX.V income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 1991788.00
RX.V income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 9012232.00
RX.V income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 1991788.00
RX.V cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: 9012232.00
RX.V cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: 1991788.00
RX.V income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: 9012232.00
RX.V income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 1991788.00
RX.V cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: -335764.00
RX.V cash_flow (quarterly, 2025-12-31) — Net Intangibles Purchase And Sale: -3640.00
RX.V income_statement (annual, 2025-12-31) — Net Interest Income: 759747.00
RX.V income_statement (quarterly, 2025-12-31) — Net Interest Income: 176289.00
RX.V cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: 3780072.00
RX.V cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: 2076465.00
RX.V cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -196627.00
RX.V cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: -51774.00
RX.V cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -196627.00
RX.V cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: -51774.00
RX.V income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 759747.00
RX.V income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 176289.00
RX.V cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -793365.00
RX.V cash_flow (annual, 2025-12-31) — Net Other Investing Changes: 91996.00
RX.V cash_flow (quarterly, 2025-12-31) — Net Other Investing Changes: 0.00
RX.V balance_sheet (annual, 2025-12-31) — Net PPE: 982737.00
RX.V balance_sheet (quarterly, 2025-12-31) — Net PPE: 982737.00
RX.V cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -54044.00
RX.V cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -13723.00
RX.V balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 36668433.00
RX.V balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 36668433.00
RX.V balance_sheet (annual, 2025-12-31) — Non Current Deferred Assets: 510932.00
RX.V balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Assets: 510932.00
RX.V balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 131601.00
RX.V balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 131601.00
RX.V balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 510932.00
RX.V balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 510932.00
RX.V balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 131601.00
RX.V balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 131601.00
RX.V balance_sheet (annual, 2025-12-31) — Non Current Note Receivables: 61799.00
RX.V balance_sheet (quarterly, 2025-12-31) — Non Current Note Receivables: 61799.00
RX.V income_statement (annual, 2025-12-31) — Normalized EBITDA: 12974745.00
RX.V income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 2803495.00
RX.V income_statement (annual, 2025-12-31) — Normalized Income: 9044362.11
RX.V income_statement (quarterly, 2025-12-31) — Normalized Income: 2061840.87
RX.V cash_flow (annual, 2025-12-31) — Operating Cash Flow: 9009146.00
RX.V cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 3487434.00
RX.V cash_flow (annual, 2025-12-31) — Operating Gains Losses: 29397.00
RX.V cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: 7147.00
RX.V income_statement (annual, 2025-12-31) — Operating Income: 11313154.00
RX.V income_statement (quarterly, 2025-12-31) — Operating Income: 2389266.00
RX.V income_statement (annual, 2025-12-31) — Operating Revenue: 43051983.00
RX.V income_statement (quarterly, 2025-12-31) — Operating Revenue: 9671923.00
RX.V balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 11263255.00
RX.V balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 11263255.00
RX.V balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 23608.00
RX.V balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 23608.00
RX.V income_statement (annual, 2025-12-31) — Other Gand A: 2274974.00
RX.V income_statement (quarterly, 2025-12-31) — Other Gand A: 726775.00
RX.V income_statement (annual, 2025-12-31) — Other Income Expense: -42889.00
RX.V income_statement (quarterly, 2025-12-31) — Other Income Expense: -87167.00
RX.V balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 4797073.00
RX.V balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 4797073.00
RX.V cash_flow (annual, 2025-12-31) — Other Non Cash Items: -613389.00
RX.V cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: -25264.00
RX.V income_statement (annual, 2025-12-31) — Other Operating Expenses: 563974.00
RX.V income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 103555.00
RX.V balance_sheet (annual, 2025-12-31) — Other Properties: 276017.00
RX.V balance_sheet (quarterly, 2025-12-31) — Other Properties: 276017.00
RX.V balance_sheet (annual, 2025-12-31) — Other Receivables: 63442.00
RX.V balance_sheet (quarterly, 2025-12-31) — Other Receivables: 63442.00
RX.V balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 6857137.00
RX.V balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 6857137.00
RX.V balance_sheet (annual, 2025-12-31) — Payables: 6553365.00
RX.V balance_sheet (quarterly, 2025-12-31) — Payables: 6553365.00
RX.V balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 6553365.00
RX.V balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 6553365.00
RX.V balance_sheet (annual, 2025-12-31) — Prepaid Assets: 187977.00
RX.V balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 187977.00
RX.V income_statement (annual, 2025-12-31) — Pretax Income: 12030012.00
RX.V income_statement (quarterly, 2025-12-31) — Pretax Income: 2478388.00
RX.V cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 99176.00
RX.V cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 0.00
RX.V balance_sheet (annual, 2025-12-31) — Properties: 0.00
RX.V balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
RX.V income_statement (annual, 2025-12-31) — Provision For Doubtful Accounts: 98707.00
RX.V cash_flow (annual, 2025-12-31) — Provisionand Write Offof Assets: 98707.00
RX.V cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: -335764.00
RX.V cash_flow (quarterly, 2025-12-31) — Purchase Of Intangibles: -3640.00
RX.V cash_flow (annual, 2025-12-31) — Purchase Of Investment: -3029542.00
RX.V cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: -30394.00
RX.V cash_flow (annual, 2025-12-31) — Purchase Of PPE: -54044.00
RX.V cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -13723.00
RX.V balance_sheet (annual, 2025-12-31) — Raw Materials: 1574113.00
RX.V balance_sheet (quarterly, 2025-12-31) — Raw Materials: 1574113.00
RX.V balance_sheet (annual, 2025-12-31) — Receivables: 4536957.00
RX.V balance_sheet (quarterly, 2025-12-31) — Receivables: 4536957.00
RX.V income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 10088955.00
RX.V income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 2225569.00
RX.V income_statement (annual, 2025-12-31) — Reconciled Depreciation: 852491.00
RX.V income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 226462.00
RX.V cash_flow (annual, 2025-12-31) — Repayment Of Debt: -196627.00
RX.V cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -51774.00
RX.V cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: -215000.00
RX.V cash_flow (quarterly, 2025-12-31) — Repurchase Of Capital Stock: 780953.00
RX.V income_statement (annual, 2025-12-31) — Research And Development: 341049.00
RX.V income_statement (quarterly, 2025-12-31) — Research And Development: 76225.00
RX.V balance_sheet (annual, 2025-12-31) — Retained Earnings: 34240985.00
RX.V balance_sheet (quarterly, 2025-12-31) — Retained Earnings: 34240985.00
RX.V income_statement (annual, 2025-12-31) — Salaries And Wages: 9849923.00
RX.V income_statement (quarterly, 2025-12-31) — Salaries And Wages: 2343333.00
RX.V cash_flow (annual, 2025-12-31) — Sale Of Investment: 6809614.00
RX.V cash_flow (quarterly, 2025-12-31) — Sale Of Investment: 2106859.00
RX.V income_statement (annual, 2025-12-31) — Selling And Marketing Expense: 7454604.00
RX.V income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 1428621.00
RX.V income_statement (annual, 2025-12-31) — Selling General And Administration: 19793653.00
RX.V income_statement (quarterly, 2025-12-31) — Selling General And Administration: 4552139.00
RX.V balance_sheet (annual, 2025-12-31) — Share Issued: 11475447.00
RX.V balance_sheet (quarterly, 2025-12-31) — Share Issued: 11475447.00
RX.V income_statement (annual, 2025-12-31) — Special Income Charges: 0.00
RX.V cash_flow (annual, 2025-12-31) — Stock Based Compensation: 624613.00
RX.V cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 158830.00
RX.V balance_sheet (annual, 2025-12-31) — Stockholders Equity: 41465506.00
RX.V balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 41465506.00
RX.V balance_sheet (annual, 2025-12-31) — Tangible Book Value: 36668433.00
RX.V balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 36668433.00
RX.V income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -10758.89
RX.V income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -17114.13
RX.V income_statement (annual, 2025-12-31) — Tax Provision: 3017780.00
RX.V income_statement (quarterly, 2025-12-31) — Tax Provision: 486600.00
RX.V income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.25
RX.V income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.20
RX.V balance_sheet (annual, 2025-12-31) — Total Assets: 49439459.00
RX.V balance_sheet (quarterly, 2025-12-31) — Total Assets: 49439459.00
RX.V balance_sheet (annual, 2025-12-31) — Total Capitalization: 41465506.00
RX.V balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 41465506.00
RX.V balance_sheet (annual, 2025-12-31) — Total Debt: 841104.00
RX.V balance_sheet (quarterly, 2025-12-31) — Total Debt: 841104.00
RX.V balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 41465506.00
RX.V balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 41465506.00
RX.V income_statement (annual, 2025-12-31) — Total Expenses: 31738829.00
RX.V income_statement (quarterly, 2025-12-31) — Total Expenses: 7282657.00
RX.V balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 7973953.00
RX.V balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 7973953.00
RX.V balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 9646498.00
RX.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 9646498.00
RX.V balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 758345.00
RX.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 758345.00
RX.V income_statement (annual, 2025-12-31) — Total Operating Income As Reported: 11192911.00
RX.V income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: 2224745.00
RX.V balance_sheet (annual, 2025-12-31) — Total Tax Payable: 405458.00
RX.V balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 405458.00
RX.V income_statement (annual, 2025-12-31) — Total Unusual Items: -42889.00
RX.V income_statement (quarterly, 2025-12-31) — Total Unusual Items: -87167.00
RX.V income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -42889.00
RX.V income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -87167.00
RX.V balance_sheet (annual, 2025-12-31) — Treasury Shares Number: 212192.00
RX.V balance_sheet (quarterly, 2025-12-31) — Treasury Shares Number: 212192.00
RX.V balance_sheet (annual, 2025-12-31) — Working Capital: 32577353.00
RX.V balance_sheet (quarterly, 2025-12-31) — Working Capital: 32577353.00
RX.V income_statement (quarterly, 2026-03-31) — +Operating Expense: 6720575.00
RX.V income_statement (quarterly, 2026-03-31) — +Total Revenue: 13908182.00
RX.V balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 8104058.00
RX.V balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 6815544.00
RX.V balance_sheet (quarterly, 2026-03-31) — Accrued Interest Receivable: 590496.00
RX.V balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -2531305.00
RX.V balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 1795726.00
RX.V income_statement (quarterly, 2026-03-31) — Amortization: 394849.00
RX.V cash_flow (quarterly, 2026-03-31) — Amortization Cash Flow: 394849.00
RX.V cash_flow (quarterly, 2026-03-31) — Amortization Of Intangibles: 394849.00
RX.V income_statement (quarterly, 2026-03-31) — Amortization Of Intangibles Income Statement: 394849.00
RX.V income_statement (quarterly, 2026-03-31) — Basic Average Shares: 11336104.00
RX.V income_statement (quarterly, 2026-03-31) — Basic EPS: 0.21
RX.V cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 21794686.00
RX.V balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 1805812.00
RX.V cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -27582.00
RX.V balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 1247033.00
RX.V balance_sheet (quarterly, 2026-03-31) — Capital Stock: 8717798.00
RX.V balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 6649492.00
RX.V balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 10900082.00
RX.V cash_flow (quarterly, 2026-03-31) — Cash Dividends Paid: -619481.00
RX.V balance_sheet (quarterly, 2026-03-31) — Cash Equivalents: 508138.00
RX.V balance_sheet (quarterly, 2026-03-31) — Cash Financial: 6141354.00
RX.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 1422449.00
RX.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -19328248.00
RX.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: 2721393.00
RX.V cash_flow (quarterly, 2026-03-31) — Change In Account Payable: 115751.00
RX.V cash_flow (quarterly, 2026-03-31) — Change In Income Tax Payable: 807791.00
RX.V cash_flow (quarterly, 2026-03-31) — Change In Inventory: 742002.00
RX.V cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: 400118.00
RX.V cash_flow (quarterly, 2026-03-31) — Change In Payable: 923542.00
RX.V cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: 923542.00
RX.V cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -570450.00
RX.V cash_flow (quarterly, 2026-03-31) — Change In Receivables: -1553201.00
RX.V cash_flow (quarterly, 2026-03-31) — Change In Tax Payable: 807791.00
RX.V cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -57989.00
RX.V cash_flow (quarterly, 2026-03-31) — Changes In Cash: -15184406.00
RX.V balance_sheet (quarterly, 2026-03-31) — Common Stock: 8717798.00
RX.V cash_flow (quarterly, 2026-03-31) — Common Stock Dividend Paid: -619481.00
RX.V balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 44993439.00
RX.V cash_flow (quarterly, 2026-03-31) — Common Stock Payments: -1401000.00
RX.V income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 3739946.00
RX.V balance_sheet (quarterly, 2026-03-31) — Current Assets: 31323158.00
RX.V balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 433838.00
RX.V balance_sheet (quarterly, 2026-03-31) — Current Debt: 4000000.00
RX.V balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 4433838.00
RX.V balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 935822.00
RX.V balance_sheet (quarterly, 2026-03-31) — Current Deferred Revenue: 935822.00
RX.V balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 16563733.00
RX.V cash_flow (quarterly, 2026-03-31) — Deferred Income Tax: -25147.00
RX.V cash_flow (quarterly, 2026-03-31) — Deferred Tax: -25147.00
RX.V cash_flow (quarterly, 2026-03-31) — Depreciation: 94112.00
RX.V cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 488961.00
RX.V income_statement (quarterly, 2026-03-31) — Depreciation Amortization Depletion Income Statement: 488961.00
RX.V cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 488961.00
RX.V income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 488961.00
RX.V income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 94112.00
RX.V income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 11597602.00
RX.V income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.20
RX.V income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 2344819.00
RX.V income_statement (quarterly, 2026-03-31) — EBIT: 3316917.00
RX.V income_statement (quarterly, 2026-03-31) — EBITDA: 3805878.00
RX.V cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: 39212.00
RX.V cash_flow (quarterly, 2026-03-31) — End Cash Position: 6649492.00
RX.V cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 1422449.00
RX.V balance_sheet (quarterly, 2026-03-31) — Finished Goods: 10324776.00
RX.V balance_sheet (quarterly, 2026-03-31) — Foreign Currency Translation Adjustments: -145455.00
RX.V cash_flow (quarterly, 2026-03-31) — Free Cash Flow: 2693811.00
RX.V cash_flow (quarterly, 2026-03-31) — Gain Loss On Investment Securities: -39645.00
RX.V income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: -24506.00
RX.V balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: -145455.00
RX.V income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 3998327.00
RX.V balance_sheet (quarterly, 2026-03-31) — Goodwill: 3750000.00
RX.V balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 25578234.00
RX.V balance_sheet (quarterly, 2026-03-31) — Gross PPE: 4239325.00
RX.V income_statement (quarterly, 2026-03-31) — Gross Profit: 10168236.00
RX.V balance_sheet (quarterly, 2026-03-31) — Hedging Assets Current: 5553.00
RX.V balance_sheet (quarterly, 2026-03-31) — Held To Maturity Securities: 3293957.00
RX.V cash_flow (quarterly, 2026-03-31) — Income Tax Paid Supplemental Data: 157838.00
RX.V balance_sheet (quarterly, 2026-03-31) — Income Tax Payable: 1273121.00
RX.V income_statement (quarterly, 2026-03-31) — Insurance And Claims: 63574.00
RX.V income_statement (quarterly, 2026-03-31) — Interest Expense: 31616.00
RX.V income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 31616.00
RX.V income_statement (quarterly, 2026-03-31) — Interest Income: 166792.00
RX.V income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 166792.00
RX.V cash_flow (quarterly, 2026-03-31) — Interest Paid Cff: -31616.00
RX.V cash_flow (quarterly, 2026-03-31) — Interest Received Cfi: 232918.00
RX.V balance_sheet (quarterly, 2026-03-31) — Inventory: 11291008.00
RX.V balance_sheet (quarterly, 2026-03-31) — Invested Capital: 48993439.00
RX.V cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -19328248.00
RX.V balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 3293957.00
RX.V balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 3293957.00
RX.V cash_flow (quarterly, 2026-03-31) — Issuance Of Debt: 8000000.00
RX.V balance_sheet (quarterly, 2026-03-31) — Leases: 724062.00
RX.V balance_sheet (quarterly, 2026-03-31) — Line Of Credit: 4000000.00
RX.V balance_sheet (quarterly, 2026-03-31) — Loans Receivable: 63694.00
RX.V balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 813195.00
RX.V balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 813195.00
RX.V cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -69428.00
RX.V balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 1222510.00
RX.V cash_flow (quarterly, 2026-03-31) — Net Business Purchase And Sale: -22157872.00
RX.V cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: -1401000.00
RX.V income_statement (quarterly, 2026-03-31) — Net Income: 2344819.00
RX.V income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 2344819.00
RX.V income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 2344819.00
RX.V income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 2344819.00
RX.V income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 2344819.00
RX.V cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: 2344819.00
RX.V income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 2344819.00
RX.V cash_flow (quarterly, 2026-03-31) — Net Intangibles Purchase And Sale: 0.00
RX.V income_statement (quarterly, 2026-03-31) — Net Interest Income: 135176.00
RX.V cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: 2606547.00
RX.V cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: 3930572.00
RX.V cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: -69428.00
RX.V income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 135176.00
RX.V cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -481210.00
RX.V cash_flow (quarterly, 2026-03-31) — Net Other Investing Changes: 17741.00
RX.V balance_sheet (quarterly, 2026-03-31) — Net PPE: 1708020.00
RX.V cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -27582.00
RX.V cash_flow (quarterly, 2026-03-31) — Net Short Term Debt Issuance: 4000000.00
RX.V balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 19415205.00
RX.V balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Assets: 526742.00
RX.V balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 121543.00
RX.V balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 526742.00
RX.V balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 121543.00
RX.V balance_sheet (quarterly, 2026-03-31) — Non Current Note Receivables: 61799.00
RX.V income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 4103414.00
RX.V income_statement (quarterly, 2026-03-31) — Normalized Income: 2557179.47
RX.V cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: 2721393.00
RX.V cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: -39645.00
RX.V income_statement (quarterly, 2026-03-31) — Operating Income: 3447661.00
RX.V income_statement (quarterly, 2026-03-31) — Operating Revenue: 13908182.00
RX.V balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 11434874.00
RX.V balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 1816894.00
RX.V income_statement (quarterly, 2026-03-31) — Other Gand A: 698682.00
RX.V income_statement (quarterly, 2026-03-31) — Other Income Expense: -297536.00
RX.V balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 21828234.00
RX.V cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: -136216.00
RX.V balance_sheet (quarterly, 2026-03-31) — Other Properties: 486941.00
RX.V balance_sheet (quarterly, 2026-03-31) — Other Receivables: 81035.00
RX.V balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 4250590.00
RX.V balance_sheet (quarterly, 2026-03-31) — Payables: 9377179.00
RX.V balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 9377179.00
RX.V balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 1575746.00
RX.V income_statement (quarterly, 2026-03-31) — Pretax Income: 3285301.00
RX.V cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 25184.00
RX.V balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
RX.V income_statement (quarterly, 2026-03-31) — Provision For Doubtful Accounts: 661.00
RX.V cash_flow (quarterly, 2026-03-31) — Provisionand Write Offof Assets: 661.00
RX.V cash_flow (quarterly, 2026-03-31) — Purchase Of Business: -22157872.00
RX.V cash_flow (quarterly, 2026-03-31) — Purchase Of Intangibles: 0.00
RX.V cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -27582.00
RX.V balance_sheet (quarterly, 2026-03-31) — Raw Materials: 966232.00
RX.V balance_sheet (quarterly, 2026-03-31) — Receivables: 7550769.00
RX.V income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 3739946.00
RX.V income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 488961.00
RX.V cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -4069428.00
RX.V cash_flow (quarterly, 2026-03-31) — Repurchase Of Capital Stock: -1401000.00
RX.V income_statement (quarterly, 2026-03-31) — Research And Development: 0.00
RX.V income_statement (quarterly, 2026-03-31) — Restructuring And Mergern Acquisition: 273030.00
RX.V balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 34625370.00
RX.V income_statement (quarterly, 2026-03-31) — Salaries And Wages: 3236071.00
RX.V cash_flow (quarterly, 2026-03-31) — Sale Of Investment: 2606547.00
RX.V income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 2232626.00
RX.V income_statement (quarterly, 2026-03-31) — Selling General And Administration: 6230953.00
RX.V balance_sheet (quarterly, 2026-03-31) — Share Issued: 11613701.00
RX.V cash_flow (quarterly, 2026-03-31) — Short Term Debt Issuance: 8000000.00
RX.V cash_flow (quarterly, 2026-03-31) — Short Term Debt Payments: -4000000.00
RX.V income_statement (quarterly, 2026-03-31) — Special Income Charges: -273030.00
RX.V cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 145949.00
RX.V balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 44993439.00
RX.V balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 19415205.00
RX.V income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -85175.53
RX.V income_statement (quarterly, 2026-03-31) — Tax Provision: 940482.00
RX.V income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.29
RX.V balance_sheet (quarterly, 2026-03-31) — Total Assets: 62491910.00
RX.V balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 44993439.00
RX.V balance_sheet (quarterly, 2026-03-31) — Total Debt: 5247033.00
RX.V balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 44993439.00
RX.V income_statement (quarterly, 2026-03-31) — Total Expenses: 10460521.00
RX.V balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 17498471.00
RX.V balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 31168752.00
RX.V balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 934738.00
RX.V income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: 3150125.00
RX.V balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 1273121.00
RX.V income_statement (quarterly, 2026-03-31) — Total Unusual Items: -297536.00
RX.V income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -297536.00
RX.V balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 178827.00
RX.V balance_sheet (quarterly, 2026-03-31) — Working Capital: 14759425.00
RXL.AX cash_flow (annual, 2021-06-30) — Classesof Cash Receiptsfrom Operating Activities: -374000.00
RXL.AX balance_sheet (annual, 2021-06-30) — Construction In Progress: 0.00
RXL.AX balance_sheet (annual, 2021-06-30) — Employee Benefits: 36000.00
RXL.AX balance_sheet (annual, 2021-06-30) — Leases: 205000.00
RXL.AX balance_sheet (annual, 2021-06-30) — Long Term Capital Lease Obligation: 491000.00
RXL.AX balance_sheet (annual, 2021-06-30) — Long Term Debt And Capital Lease Obligation: 491000.00
RXL.AX cash_flow (annual, 2021-06-30) — Net Investment Purchase And Sale: 156000.00
RXL.AX cash_flow (annual, 2021-06-30) — Net Other Investing Changes: -1807000.00
RXL.AX balance_sheet (annual, 2021-06-30) — Non Current Accounts Receivable: 1109000.00
RXL.AX balance_sheet (annual, 2021-06-30) — Non Current Pension And Other Postretirement Benefit Plans: 36000.00
RXL.AX cash_flow (annual, 2021-06-30) — Other Cash Receiptsfrom Operating Activities: -374000.00
RXL.AX balance_sheet (annual, 2021-06-30) — Other Current Liabilities: 116000.00
RXL.AX balance_sheet (annual, 2021-06-30) — Other Non Current Assets: 3210000.00
RXL.AX balance_sheet (annual, 2021-06-30) — Prepaid Assets: 36000.00
RXL.AX cash_flow (annual, 2021-06-30) — Sale Of Investment: 156000.00
RXL.AX cash_flow (annual, 2021-06-30) — Sale Of PPE: 2000.00
RXL.AX income_statement (annual, 2022-06-30) — +Operating Expense: 10619000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Accounts Payable: 847000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Accumulated Depreciation: -391000.00
RXL.AX income_statement (annual, 2022-06-30) — Basic Average Shares: 162447244.00
RXL.AX income_statement (annual, 2022-06-30) — Basic EPS: -0.09
RXL.AX cash_flow (annual, 2022-06-30) — Beginning Cash Position: 11913000.00
RXL.AX cash_flow (annual, 2022-06-30) — Capital Expenditure: -591000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Capital Lease Obligations: 491000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Capital Stock: 64830000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Cash And Cash Equivalents: 4441000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Cash Cash Equivalents And Short Term Investments: 4441000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Cash Financial: 4441000.00
RXL.AX cash_flow (annual, 2022-06-30) — Cash Flow From Continuing Financing Activities: 3885000.00
RXL.AX cash_flow (annual, 2022-06-30) — Cash Flow From Continuing Investing Activities: 3174000.00
RXL.AX cash_flow (annual, 2022-06-30) — Cash Flowsfromusedin Operating Activities Direct: -14531000.00
RXL.AX cash_flow (annual, 2022-06-30) — Changes In Cash: -7472000.00
RXL.AX cash_flow (annual, 2022-06-30) — Classesof Cash Payments: -14533000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Common Stock: 64830000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Common Stock Equity: 14327000.00
RXL.AX cash_flow (annual, 2022-06-30) — Common Stock Issuance: 4217000.00
RXL.AX cash_flow (annual, 2022-06-30) — Common Stock Payments: -227000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Current Assets: 4524000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Current Capital Lease Obligation: 149000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Current Debt And Capital Lease Obligation: 149000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Current Liabilities: 1211000.00
RXL.AX income_statement (annual, 2022-06-30) — Depreciation Amortization Depletion Income Statement: 155000.00
RXL.AX income_statement (annual, 2022-06-30) — Depreciation And Amortization In Income Statement: 155000.00
RXL.AX income_statement (annual, 2022-06-30) — Depreciation Income Statement: 155000.00
RXL.AX income_statement (annual, 2022-06-30) — Diluted Average Shares: 162447244.00
RXL.AX income_statement (annual, 2022-06-30) — Diluted EPS: -0.09
RXL.AX income_statement (annual, 2022-06-30) — EBIT: -13215000.00
RXL.AX income_statement (annual, 2022-06-30) — EBITDA: -13060000.00
RXL.AX income_statement (annual, 2022-06-30) — Earnings From Equity Interest: -695000.00
RXL.AX cash_flow (annual, 2022-06-30) — End Cash Position: 4441000.00
RXL.AX cash_flow (annual, 2022-06-30) — Financing Cash Flow: 3885000.00
RXL.AX cash_flow (annual, 2022-06-30) — Free Cash Flow: -15122000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Gains Losses Not Affecting Retained Earnings: 14834000.00
RXL.AX income_statement (annual, 2022-06-30) — General And Administrative Expense: 2706000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Gross PPE: 12317000.00
RXL.AX income_statement (annual, 2022-06-30) — Impairment Of Capital Assets: 1774000.00
RXL.AX income_statement (annual, 2022-06-30) — Interest Expense: 735000.00
RXL.AX income_statement (annual, 2022-06-30) — Interest Expense Non Operating: 735000.00
RXL.AX income_statement (annual, 2022-06-30) — Interest Income: 2000.00
RXL.AX income_statement (annual, 2022-06-30) — Interest Income Non Operating: 2000.00
RXL.AX cash_flow (annual, 2022-06-30) — Interest Received Direct: 2000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Invested Capital: 14327000.00
RXL.AX cash_flow (annual, 2022-06-30) — Investing Cash Flow: 3174000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Investments And Advances: 1776000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Investmentsin Associatesat Cost: 1776000.00
RXL.AX cash_flow (annual, 2022-06-30) — Issuance Of Capital Stock: 4217000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Long Term Capital Lease Obligation: 342000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Long Term Debt And Capital Lease Obligation: 342000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Long Term Equity Investment: 1776000.00
RXL.AX balance_sheet (annual, 2022-06-30) — Long Term Provisions: 5358000.00